Novo is among the limited partners for Eir Ventures, which has launched with $86m to invest in life sciences technology startups.

Sweden-based venture capital firm Eir Ventures raised €76m ($86m) on Friday for the first close of a life sciences-oriented fund backed by pharmaceutical firm Novo.

The fund’s limited partners also include the European Union-owned European Investment Fund, Swedish government-founded VC firm Saminvest and Danish Growth Fund, the state-owned investment fund also known as Vækstfonden.

Eir Ventures will seek out innovative university research and intends to work alongside Nordics-based incubators. More broadly, it anticipates participation in deals across the region as…